Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.

Coronavirus-related news from across the Medical Sciences Division

Major rise in public support for COVID vaccine – Oxford study

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Oxford-led technology to help those at high risk from Covid-19

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.

World Health Organization lists Oxford coronavirus vaccine for emergency use

The Oxford / AstraZeneca vaccine has today been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65.

Oxford University extends COVID-19 vaccine study to children

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Drug trial that could improve respiratory recovery from COVID-19 now underway

A clinical trial has commenced this week to test whether a drug called Almitrine can help people who are seriously ill with COVID-19 to recover from the disease.

Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests

Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.

NHS COVID-19 contact tracing app averted between 200,000 and 900,000 infections, estimates infectious disease experts

A team of medical research and statistical modelling experts at Oxford University and the Alan Turing Institute have conducted a joint analysis to assess the impact of the NHS COVID-19 contact tracing app.